Skip to content
AnalystLens

Exelixis 8-K Report, Financial Results (Oct 29, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 29, 2026
Period End
October 29, 2026
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 8-K filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Nasdaq: EXEL) reported third-quarter 2026 financial results on October 29, 2026, furnishing a press release as Exhibit 99.1.

Total revenues were $658.7 milliona, up from $597.8 million a year earlier, driven by net product revenues of $604.9 million (compared with $542.9 million), which the company attributed to higher sales volume and a higher average net selling price. Collaboration revenues were $53.8 million, versus $54.8 million. GAAP net income was $218.1 million, or $0.85 per diluted share, compared with $193.6 million, or $0.69 per diluted share, a year earlier.

Non-GAAP diluted EPS, which excludes stock-based compensation net of tax, was $0.94b. Research and development expenses rose to $209.5 million and selling, general and administrative expenses rose to $154.6 million. The company updated its 2026 guidance, lowering the expected effective tax rate to 16% to 18% from 21% to 23%, while raising cost of goods sold to approximately 4% of net product revenues from 3.5% to 4.5%.

Total revenue guidance ($2.500 billion to $2.550 billionc) and net product revenue guidance ($2.300 billion to $2.350 billion) were unchanged and do not reflect any potential zanzalintinib launch. The FDA is reviewing the zanzalintinib NDA for previously treated metastatic colorectal cancer in combination with atezolizumab, with a PDUFA target action date of March 3, 2027 after a three-month extension. The company also disclosed a $750 million stock repurchase authorization from May 2026, under which it had bought back $402.1 million at an average price of $54.03 per share by quarter end.

The filing also reports a settlement and license agreement with Azurity Pharmaceuticals, entered October 28, 2026, granting a license beginning December 1, 2030, and a Federal Circuit decision in August 2026 upholding patents against MSN Laboratories, which sets an effective date for any MSN ANDA approval of no earlier than January 15, 2030. Topline results from the phase 3 STELLAR-304 trial are expected in the first quarter of 2027.

Key Highlights

  1. Total revenues of $658.7 million for Q3 2026, versus $597.8 million in Q3 2025; net product revenues were $604.9 million, versus $542.9 million.
  2. GAAP diluted EPS of $0.85 and non-GAAP diluted EPS of $0.94, versus GAAP diluted EPS of $0.69 in the prior-year quarter.
  3. Updated 2026 guidance: effective tax rate lowered to 16%-18% (from 21%-23%) and COGS raised to about 4% of net product revenues (from 3.5%-4.5%); revenue and R&D/SG&A guidance unchanged.
  4. FDA PDUFA target action date for zanzalintinib plus atezolizumab in previously treated metastatic CRC is March 3, 2027, following a three-month review extension.
  5. Stock repurchases of $402.1 million under the $750 million May 2026 program at an average price of $54.03 per share as of quarter end.
  6. Settlement with Azurity Pharmaceuticals entered October 28, 2026, with a license beginning December 1, 2030; Federal Circuit affirmed patent validity in the MSN litigation, setting no earlier than January 15, 2030 for any MSN ANDA approval.
  7. Phase 3 STELLAR-304 topline results in nccRCC expected in Q1 2027.

Frequently Asked Questions

  1. How did Exelixis perform in the third quarter of 2026?

    Total revenues were $658.7 million, up from $597.8 million a year earlier. Net product revenues rose to $604.9 million from $542.9 million, primarily due to higher sales volume and a higher average net selling price. GAAP net income was $218.1 million, or $0.85 per diluted share, compared with $0.69 per diluted share in Q3 2025.

  2. Did Exelixis change its 2026 financial guidance?

    Yes, in part. The effective tax rate guidance was lowered to 16% to 18% from 21% to 23%, and cost of goods sold guidance was raised to approximately 4% of net product revenues from 3.5% to 4.5%. Total revenue guidance of $2.500 billion to $2.550 billion and net product revenue guidance of $2.300 billion to $2.350 billion were unchanged, and these do not reflect any zanzalintinib launch revenue.

  3. What is the regulatory status of zanzalintinib in colorectal cancer?

    The FDA is reviewing the NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic CRC. In September 2026 the review period was extended by three months after Exelixis submitted updated safety and efficacy data in response to an FDA information request, and the PDUFA target action date is now March 3, 2027.

  4. How much stock has Exelixis repurchased?

    Under the May 2026 program, authorized for up to $750 million before December 31, 2027, Exelixis had repurchased $402.1 million of common stock at an average price of $54.03 per share as of the end of Q3 2026. Since the first program in March 2023, it has repurchased a total of $3.2 billion, retiring 97.8 million shares at an average price of $32.25 per share.

  5. What did the Azurity and MSN legal developments mean for Exelixis?

    Exelixis entered a settlement and license agreement with Azurity on October 28, 2026, granting Azurity a license to market its proposed 505(b)(2) NDA product in the U.S. beginning December 1, 2030, if approved. In the MSN patent case, the Federal Circuit upheld patents Nos. 11,091,439, 11,091,440 and 11,098,015, so any final FDA approval of MSN's ANDA may not take effect before January 15, 2030, subject to further proceedings. A separate trial on U.S. Patent No. 12,128,039 is scheduled for November 2026.